Sfoglia per AUTORE
BUFFONI L
Collezione AOU San Luigi di Orbassano

  

Items : 13

Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2024 Jan;187:107444. doi: 10.1016/j.lungcan.2023.107444. Epub 2023 Dec 15.

2024
ASL Alessandria
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Malapelle U; Novello S; Garbo E; Agustoni F; Gori S; Grisanti S; Catania C; Buffoni L; Buosi R; Brambilla M; Vavalà T; Scotti V; Carta A; Cerea G; Tiseo M; Delmonte A; Russo A; Cortinovis D; Chiari R; Metro G; Citarella F; Genova C; Roca E; Pilotto S; Bria E; Pelizzari G; Sini C; Galetta D; Bulotta A; et alii...

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA). in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02529-2. doi: 10.1016/j.jtho.2024.12.010.

2024
ASL Cuneo 2
ASL Asti
AOU San Luigi di Orbassano

Novello S; Scagliotti G; Righi L; Vallone S; Malapelle U; Volante M; Giannarelli D; Mohorcic K; Meoni G; Scotti V; Linardou H; Bettini AC; Ramizi KM; Secen N; Comanescu A; Felip E; Paz-Ares L; Pignataro D; Araujo A; Barbieri V; Mazilu L; Buffoni L; Taveggia PA; Simionato F; Roca E; Sini C; Tabbò F; Reale ML; Zambelli V; et alii...

Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling. in BMC cancer / BMC Cancer. 2022 Nov 24;22(1):1212. doi: 10.1186/s12885-022-10296-x.

2022
AOU San Luigi di Orbassano

Caccialanza R; Cereda E; Agustoni F; Klersy C; Casirati A; Montagna E; Carnio S; Novello S; Milella M; Pilotto S; Trestini I; Buffoni L; Ferrari A; Pedrazzoli P;

Immune Checkpoint Inhibitors and Opioids in Patients with Solid Tumours: Is Their Association Safe? A Systematic Literature Review. in Healthcare (Basel, Switzerland) / Healthcare (Basel). 2022 Dec 30;11(1):116. doi: 10.3390/healthcare11010116.

2022
AOU San Luigi di Orbassano

Cani M; Bironzo P; Garetto F; Buffoni L; Cotogni P;

A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2022 Apr;172:103639. doi: 10.1016/j.critrevonc.2022.103639. Epub 2022 Feb 19

2022
ASL Asti
AOU San Luigi di Orbassano

Passiglia F; Novello S; Buffoni L; Carnio S; Capelletto E; Zichi C; Reale ML; Artusio E; Olmetto E; Bungaro M; Paratore C; Bertaglia V; Audisio M; Rapetti SG; Pignataro D; Curcio H; De Luca E; Bironzo P; Tagliamento M; Scagliotti GV; Di Maio M;

Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings. in La Radiologia medica / Radiol Med. 2020 Feb;125(2):214-219. doi: 10.1007/s11547-019-01094-w. Epub 2019 Oct 11.

2020
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Scotti V; Piperno G; Filippi AR; Tindara F; Ferrari K; Chiari R; Bearz A; Passaro A; Trovò M; Vattemi E; Bezzi M; Comin C; Andolina M; Badellino S; Ramella S; Buffoni L; Genovesi D; Giaj-Levra N; Bruni A; Borghetti P; Franceschini D;

Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era. in Current oncology reports / Curr Oncol Rep. 2019 Nov 25;21(12):107. doi: 10.1007/s11912-019-0852-9.

2019
AOU San Luigi di Orbassano

Friedlaender A; Banna GL; Buffoni L; Addeo A;

Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors. in Neurology / Neurology. 2019 Jul 30;93(5):217-219. doi: 10.1212/WNL.0000000000007866. Epub 2019 Jun 27.

2019
AOU San Luigi di Orbassano

Pellerino A; Buffoni L; Rudà R; Soffietti R;

Corrigendum to "Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario" [Crit. Rev. Oncol./Hematol. 122 (February) (2018) 150-156]. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2019 Jul;139:158. doi: 10.1016/j.critrevonc.2018.06.018. Epub 2018 Nov 2.

2019
AOU San Luigi di Orbassano

Addeo A; Tabbò F; Robinson T; Buffoni L; Novello S;

Listening understanding and acting (lung): focus on communicational issue in thoracic oncology. in Translational cancer research / Transl Cancer Res. 2019 Jan;8(Suppl 1):S16-S22. doi: 10.21037/tcr.2018.12.32.

2019
AOU San Luigi di Orbassano
AOU Novara

Romano G; Roca E; Morabito A; Montrone M; Minotti V; Migliorino MR; Melotti B; Mazzanti P; Martelli O; Malorgio F; Mancuso G; Landi L; Irtelli L; Gregorc V; Gilli M; Franchina T; Del Conte A; D'Argento E; Cusmai A; Danesi R; Costanzo R; Cortinovis D; Carta A; Bulotta A; Buffoni L; Borra G; Bettini A; Bianco R; Barbieri V; et alii...

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2018 Feb;122:150-156. doi: 10.1016/j.critrevonc.2017.12.015. Epub 2017 Dec 3

2018
AOU San Luigi di Orbassano

Buffoni L; Novello S; Robinson T; Tabbò F; Addeo A;

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2017 Sep;111:30-37. doi: 10.1016/j.lungcan.2017.06.009. Epub 2017 Jun 16.

2017
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Novello S; Maiello E; Catino A; Cortinovis D; Pisconti S; Bordi P; Migliorino MR; Franchina T; Delmonte A; Ceribelli A; Buffoni L; Riccardi F; Scotti V; Rossi G; Gregorc V; Bria E; Di Maio M; Rossi A; Graziano P; Arizio F; Tiseo M; Galetta D; Gobbini E; Gobbini E; Galetta D; Tiseo M; Graziano P; Rossi A; Bria E; et alii...

Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward? in Current treatment options in oncology / Curr Treat Options Oncol. 2016 Oct;17(10):54. doi: 10.1007/s11864-016-0429-x.

2016
ASL Cuneo 1
AOU San Luigi di Orbassano

Novello S; Vavalà T; Buffoni L;